Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751780 | 0.98 | RAB9A (0.62) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL751658 | 0.95 | RAB9A (0.57) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3759188 | 0.83 | POLB (0.69) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL750953 | 0.83 | CYP2C9 (0.71) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL420582 | 0.81 | RAB9A (0.69) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4051171 | 0.81 | RAB9A (0.69) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL25855522 | 0.80 | RAB9A (0.72) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4776281 | 0.79 | CYP2C9 (0.71) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL491293 | 0.79 | KMT2A (1.00) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8363751 | 0.79 | RAB9A (1.00) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | claimed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | claimed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | claimed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | claimed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | claimed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | claimed |
| EP-2850068-A1 | GPR17 RECEPTOR MODULATORS. | Universita' degli Studi di Milano (IT) | 2015-03-25 | — | — | EP | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013167177-A1 | GPR17 RECEPTOR MODULATORS. | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2013-11-14 | — | — | WO | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | claimed |
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | ARIVA MED GMBH (AT) | 2024-06-27 | — | — | US | disclosed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | MTNR1A, MSH6, MSH2 | RAB9A 284/4885NPC1 768/4885KMT2A 3476/4885 |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | RAB9A 4376/4885NPC1 63/4885KMT2A 2379/4885 |
| US-20150141410-A1 | GPR17 Receptor Modulators | GPR65, GPR27, GPR17 | RAB9A 2491/4885NPC1 868/4885KMT2A 3467/4885 |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | RAB9A 677/4885NPC1 732/4885KMT2A 2120/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | RAB9A 1291/4885NPC1 4572/4885KMT2A 1237/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | RAB9A 1554/4885NPC1 3035/4885KMT2A 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.